Lataa...
A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
Epidermal growth factor receptor variant III (EGFRvIII) is highly and specifically expressed in a subset of lethal glioblastoma (GBM), making the receptor a unique therapeutic target for GBM. Recently, bispecific antibodies (BsAbs) have shown exciting clinical benefits in cancer immunotherapy. Here,...
Tallennettuna:
| Julkaisussa: | Biomedicines |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8230177/ https://ncbi.nlm.nih.gov/pubmed/34204931 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines9060640 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|